Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Spanish institute to lead EU research projects

This article was originally published in Scrip

Executive Summary

The Institute for Research in Biomedicine in Barcelona, Spain, is to co-ordinate two European health research projects which aim to fight malaria and diabetes. The European Commissionwill award the institute €5 million between 2009 and 2011 for the projects, both of which are to be formed of a consortium of researchers. The first project, called Mephitis, will look into new antimalarial compounds. Specifically, it aims to study the formation of proteins in the parasite involved in the transmission of the disease to help identify the components needed for inhibiting the process. The second venture – the MITIN Project – aims to identify the processes that result in insulin resistance, with bioinformatics playing a key role. Both projects are part of the EU's Seventh Research Framework Programme (FP7).

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC007864

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel